Solomon Seeks $3.8M From Spirogen For AstraZeneca Deal

Law360, New York (May 02, 2014, 8:56 PM ET) -- Investment banking advisory firm Peter J. Solomon Co. is suing a British biotech company, formerly known as Spirogen Ltd., seeking $3.75 million in fees for advising the company in its $200 million sale to an AstraZeneca PLC subsidiary, according to a complaint filed in New York court Friday.

Solomon Co. alleged it had a contract with Spirogen, which is now operating as a British company called ADC Products Ltd., to provide financial advisory services in connection with a possible sale of the company but never received...
To view the full article, register now.